GROWTH HORMONE
L-arginine supplementation can 2 3 (but does not always 4 ) increase serum growth hormone concentrations in humans.
One well-designed study compared men to women with various growth hormone secretagogues, including arginine (30 grams IV), exercise, growth hormone releasing hormone, somatostatin rebound, compared to rest and saline for each individual. The impressive thing is that the exercise stimulus was roughly equivalent to 30 grams of intravenous L-arginine, a dose several times more and via a different route than we are advocating.
(Even my own husband, a Cardiococktail junky, takes only 20 grams at most each day, and he does not yet mainline the stuff.) If you enjoy a welldesigned, well-executed study, you'll enjoy reading this article. The link to the full text is in the footnotes.
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In another randomized, placebo-controlled study in healthy men, placebo was compared to Arginine alone, placebo +exercise, or Arginine + exercise.
The dose was 7 grams oral Arginine. The exercise yielded a greater growth hormone response than exercise + Arginine or Arginine alone. 6 It is true that patients who received growth hormone injections in the past are considered at a higher risk of various cancers, including leukemia. What is not known is whether the growth hormone which may be secreted after arginine supplementation will trigger the same potential for tumor support as a recombinant injection. And since the growth hormone produced in response to oral arginine would be less than exercise stimulation, are we going to tell them not to exercise because the growth hormone produced by the exercise might promote cancer?
SPECIAL CASES: MELANOMA AND HEPATOCELLULAR CARCINOMA
These are the only group of people whom I think should be warned against using L-arginine. Melanoma, hepatocellular carcinoma and possibly leukemic cells 7 require L-arginine to be supplied for their growth. They lack the enzymes necessary to convert L-citrulline into L-arginine, and sometimes from L-arginine into nitric oxide. 8 9 This particular characteristic has already been exploited in tumor research with good results. Interestingly, in a mouse model if these cell types are transgenically infected with the enzymes to convert L-arginine into nitric oxide they LOSE THE ABILITY TO
METASTASIZE
. 10 Yet NOS activity is higher in melanoma than melanocyte cell lines in vitro.
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A number of trials have used arginase (an enzyme responsible for changing arginine to ornithine) to treat hepatocellular carcinomas. These have resulted in responses with regression in both metastasis and the primary tumor. 12 An arginine diiminase (another enzyme which breaks down arginine) from Mycoplasma has been used in multiple trials. One trial shrank a tumor from an unresectable to a surgically resectable size. Other studies show inhibition of hepatocellular carcinoma and malignant melanoma cells both in vitro and in vivo.
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Human Studies
What happens if we give L-arginine to real, live cancer patients? Many studies have utilized L-arginine as a component in perioperative nutrition and immunomodulation, and some have even used it as an adjunct to chemotherapy. After explaining immunonutrition and the immune dysfunction in cancer, I'll talk about some specific cancer studies using Larginine supplementation.
Immunonutrition is the concept of optimizing the immune system through giving proper nutrients, nutrients known to improve blood components known to fight cancer or infection, such as IgG and IgM, Natual Killer (NK), Lymphokine-Associated Killer (LAK), and T-cytotoxic cells, while diminishing the circulating components known to undermine host defenses such as T suppressor cells and IL-6. L-arginine appears again and again as a beneficial component of these formulations. These studies support the safety of formulae containing L-arginine, reveal the improvement of patients' immune markers over control groups who did not receive immunonutrition, and a few even suggest a trend toward better survival in cancer patients.
It is known that there is immune dysfunction in cancer; it is believed that poor immune function allows cancer to thrive in the body. How does this happen? And how does L-arginine interact with the immune system in cancer?
Myleoid cells
Immature myeloid cells actually protect tumors. When exposed to the environment of the tumor, they become myeloid suppressor cells resulting in poor function of immune system. They develop increased arginase activity, breaking down arginine, and making it unavailable to T-cells. Arginine is directly responsible for T-lymphocyte cell cycle progression 14 , T-cell proliferation, and production of cytokines. Since macrophages in tumors are known to secrete Arginase I, 15 it is not surprising that in cancer, T-cells have a decreased ability to proliferate and decreased production of cytokines. Arginase I also decreases expression of T-cell receptor "CD3zeta chain", 16 17 and impairs T-cell responses. In fact Arginase I is increased in tumors relative to surrounding normal tissues, and often in cancer patients' serum in general. 18 Addition of excess arginine restores T-cell proliferation, cytokine production and CD3zeta receptor expression.
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General Cancer Studies
In one study, Arginine, glutamine and omegas were supplemented in trauma, burn and cancer patients. All patients had increased lymphocytes, CD4, CD8 cells, Complement 3, IgG, and IgA; with decreased CRP. 20 Three studies (2 were double blinded) studied a mixtures of Arginine, glutamine, omeaga3, omega 6, RNA, vitamins E, C, A. 3 studies showed decreased infection rate in surgical patients (down 75%!), and hospital length of stay was 20% shorter.
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Arginine 25 grams daily was compared to glycine 43 grams of supplement in 30 cancer patients undergoing surgery. Positive mean nitrogen balance, although moderate, was achieved only in the arginine group. The immune effect was much more noticeable, with improvements in T-lymphocyte response to stimulation and increase in CD4 phenotype. 22 However, in advanced gastric cancer 30 grams daily of L-arginine for a week did not stimulate lymphocyte function. It was found to be safe in this patient population.
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Another study in patients undergoing major surgery for cancer found no difference inlymphocyte proliferation or monocyte function between Control groups, compared to groups given arginine or to arginine plus omegas.
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Thymic hormone (thymulin) levels, known to be low in cancer patients, are
improved by lysine-arginine mix. The levels ultimately were higher than in age-matched controls, and the patients had increased numbers of peripheral T-cell subsets.
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Head and Neck:
A number of head and neck cancer studies evaluated perioperative nutrition via several regimens. L-arginine was found to be safe in all cases, and generally well-tolerated. These all are supportive of the use of L-arginine in a general nutritional regimen. The entire regimen did not prolong life, but did reduce wound complications, fistulae, hospital stays and hospital costs.
One study of supplementation revealed better protein levels 26 . Another randomized study revealed increased lymphocytes, CD4, CD4/8 ratios on day 4 and CD3, CD4, CD4/8 on PO8. In a malnourished subgroup in the same study, the arginine supplemented group had decreased incidence of postoperative and wound complications and length of stay in the hospital.
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Other studies showed decreased fistulae 28 29 30 , in the groups receiving Larginine supplements. The studies had differing result regarding length of stay in the hospital.
Other studies showed no difference in nutritional or inflammatory markers between groups, 31 and no difference regarding nutritional status, complications, but a trend toward better survival in Arginine supplemented group.
32
Breast cancer patients:
Although L-arginine supplementation inhibits growth of tumors in animals, it seems to stimulate tumor protein synthesis in tumors of humans supplemented with L-arginine. 33 Nevertheless, multiple studies have been done and are currently underway using L-arginine supplementation for cancer patients. Generally, L-arginine supplementation or IV regimens have been well-tolerated and seem to improve prognosis.
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In a double-blinded, randomized, controlled study using 30 grams/day for 3 days in addition to standard chemotherapy vs placebo, no significant change was noted in response rate. However, for tumors less than 6 cm in size at One formula with Arginine, Omega-3, and RNA had better wound healing and fewer wound complications. 45 Another study of this same formula in GI surgery patients (benign and malignant disease) found no benefit.
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One study compared arginine to glutamine to a control population. While the arginine group had a higher albumin, the glutamine group had decreased postoperative morbidity. Abel T, Knechtle B, Perret C, Eser P, von Arx P, Knecht H.
Institute of Sports Medicine, Swiss Paraplegic Centre, Nottwil.
The intake of arginine aspartate has been shown to increase anabolic hormones like human growth hormone (hGH) and glucagon. The aim of our study was to investigate whether daily intake of two different dosages of arginine asparate during four weeks affects selected parameters of overtraining syndrome like performance, metabolic and endocrine parameters.
Thirty male endurance-trained athletes were included in a randomized, double-blind, placebocontrolled study and divided into three groups. During four weeks, they ingested either arginine aspartate with a high concentration (H) of 5.7 g arginine and 8.7 g aspartate, with a low concentration (L) of 2.8 g arginine and 2.2 g aspartate or placebo (P).VO(2)peak and time to exhaustion were determined on a cycling ergometer in an incremental exercise test before and after supplementation. Before and after each incremental exercise test, concentrations of hGH, glucagon, testosterone, cortisol, ferritine, lactate, and urea were measured. Compared to placebo, no significant differences on endurance performance (VO(2)peak, time to exhaustion), endocrine (concentration of hGH, glucagon, cortisol, and testosterone) and metabolic parameters (concentration of lactate, ferritine, and urea) were found after chronic arginine aspartate supplementation. The chronic intake of arginine asparate during four weeks by male endurance athletes showed independent of dosage no influence on performance, selected metabolic or endocrine parameters. Consequently, there seems to be no apparent reason why the supplementation of arginine aspartate should be an effective ergogenic aid. The practice of using arginine aspartate as potential ergogenics should be critically reevaluated. Further investigations with higher dosage and extended supplementation periods should be performed. To test whether concentrations of estradiol and testosterone predict GH responses to mechanistically distinct secretagogues in healthy older adults, we studied 16 volunteers (n = 10 men, n = 6 women, age 49-72 yr) in each of six randomly ordered sessions as follows: 1) saline;
5) Contributions
2) l-arginine; 3) aerobic exercise; 4) GHRH; 5) GH-releasing peptide (GHRP)-2; and 6) somatostatin-induced rebound. Statistical comparisons disclosed that stimulus type (P < 0.001) and the interaction between gender and stimulus type (P = 0.023) determine GH secretion. In women, each secretagogue, except exercise and somatostatin-induced rebound, stimulated GH secretion by 2.6-to 6.4-fold over saline/rest (P < 0.023). In men, somatostatin-induced rebound drove GH secretion by 4.6-fold (P = 0.004), exercise by 16-fold (P < 0.001), and other secretagogues by 18-to 109-fold over saline/rest (each P < 0.001). Gender comparisons disclosed greater GH secretion in men than women after somatostatin-induced rebound (P = 0.008) and GHRP-2 injection (P < 0.001) and conversely greater GH secretion in women than men after saline (P = 0.013). Regression analysis showed that individual concentrations of estradiol (r = 0.80, P = 0.002) and testosterone (r = 0.63, P = 0.008) and their combination (r = 0.86, P < 0.001) strongly predict responses to GHRP-2 only. We conclude that among healthy middle-aged and older adults, the action of GHRP is uniquely determined by gender and physiological concentrations of testosterone and estradiol. This study investigated the combined effect of resistance exercise and arginine ingestion on spontaneous growth hormone (GH) release. Eight healthy male subjects were studied randomly on four separate occasions [placebo, arginine (Arg), placebo + exercise (Ex), arginine + exercise (Arg+Ex)]. Subjects had blood sampled every 10 min for 3.5 h. After baseline sampling (30 min), subjects ingested a 7-g dose of arginine or placebo (blinded, randomly assigned). On the exercise days, the subject performed 3 sets of 9 exercises, 10 repetitions at 80% one repetition maximum. Resting GH concentrations were similar on each study day. Integrated GH area under the curve was significantly higher on the Ex day (508.7 +/-169.6 min.ng/ml; P < 0.05) than on any of the other study days. Arg+Ex (260.5 +/-76.8 min.ng/ml) resulted in a greater response than the placebo day but not significantly greater than the Arg day. The GH half-life and half duration were not influenced by the stimulus administered. The GH secretory burst mass was larger, but not significantly, on the Arg, Ex, and Arg+Ex day than the placebo day. Endogenous GH production rate (Ex > Arg+Ex > Arg > placebo) was greater on the Ex and Arg+Ex day than on the placebo day (P < 0.05) but there were no differences between the Ex and Arg+Ex day.
Oral arginine alone (7 g) stimulated GH release, but a greater GH response was seen with exercise alone. The combined effect of arginine before exercise attenuates the GH response.
Autonegative feedback possibly causes a refractory period such that when the two stimuli are presented there will be suppression of the somatotrope. Nitric oxide synthase activity is up-regulated in melanoma cell lines: a potential mechanism for metastases formation.
Melanoma Res. 1996 Apr;6(2):121-6.
Joshi M, Strandhoy J, White WL.
Department of Dermatology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA.
Nitric oxide (NO) may be an important mediator of tumour angiogenesis and metastasis formation. Tumour cell derived NO may be important in the regulation of angiogenesis and vasodilatation of the blood vessels surrounding a tumour. The aims of the present study were, firstly, to determine whether malignant melanoma cells and normal melanocytes had nitric oxide synthase (NOS) activity (measured by the conversion of L-arginine to L-citrulline) and, secondly, to determine whether there was a difference in NOS activity between malignant and normal cell types. This paper assays NOS activity directly in lysates from normal human melanocyte and malignant melanoma cell lines. The enzyme activity was not inducible with bacterial lipopolysaccharide and could be heat denatured. The activity of NOS was demonstrated to be both NADPH-and calcium-dependent and it was inhibitable in a dose-dependent manner by the NOS inhibitor Nw-nitro-L-arginine methyl ester. We conclude that melanoma and melanocyte cells express a constitutive form of NOS. Finally, nitric oxide synthase activity in melanoma cell lines was found to be significantly greater than in normal melanocytes. These findings suggest that NO synthesis is elevated in malignant melanoma. An elevated NO concentration in melanoma is expected to promote metastases by maintaining a vasodilator tone in the blood vessels in and around the melanoma.
Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Myeloid suppressor cells with high arginase activity are found in tumors and spleen of mice with colon and lung cancer. These cells, described as macrophages or immature dendritic cells, deplete arginine and impair T cell proliferation and cytokine production. Although arginase activity has been described in cancer patients, it is thought to originate from tumor cells metabolizing arginine to ornithine needed to sustain rapid cell proliferation. The goal of this study was to determine whether myeloid suppressor cells producing high arginase existed in renal cell carcinoma patients. Peripheral blood mononuclear cells from 123 patients with metastatic renal cell carcinoma, prior to treatment, were found to have a significantly increased arginase activity. These patients had a markedly decreased cytokine production and expressed low levels of T cell receptor CD3zeta chain. Cell separation studies showed that the increased arginase activity was limited to a specific subset of CD11b+, CD14-, CD15+ cells with a polymorphonuclear granulocyte morphology and markers, instead of macrophages or dendritic cells described in mouse models. Furthermore, these patients had low levels of arginine and high levels of ornithine in plasma. Depletion of the CD11b+, CD14-myeloid suppressor cells reestablished T cell proliferation and CD3zeta chain expression. These results showed, for the first time, the existence of suppressor myeloid cells producing arginase in human cancer patients.
In addition, it supports the concept that blocking arginase may be an important step in the success of immunotherapy. The mean arginase activity in breast cancers (n = 80) was significantly higher than in control tissues and it accounted for 0.31 +/-0.23 U/g wet tissue and 0.083 +/-0.061 U/g (P < 0.05), respectively. With the cutoff value of 0.1 U/g wet tissue, raised arginase activity was observed in 74% of tumors. The preoperative arginase activity in blood serum from women with breast cancer was 11.2 +/-7.9 U/l (n = 115), and it was significantly higher than in 70 healthy controls,
where it was 5.7 +/-2.4 U/l (P < 0.05). With the cutoff value for normal serum arginase activity above 8.0 U/l, the activity was raised in 10% of control individuals, and in 63% of women with breast cancer. The sensitivity and specificity of the arginase test in blood serum were 63% and 60%, respectively. Two isoforms immunologically identical to human kidney arginases (Larginine amidinohydrolase) were found in both normal and cancerous breast tissues. The level of anionic form was similar in control and cancerous tissues, whereas the cationic isoform predominated in breast cancer. The cationic isoform was the only one present in serum of both ill and healthy women, and its level was higher in patients with breast cancer. Thus, it can be concluded that the cationic isoform is responsible for the increase of arginase activity in serum of 
Alexander JW.
Department of Surgery, College of Medicine, University of Cincinnati, Ohio.
Arginine, glutamine, the long chain polyunsaturated omega-3 and omega-6 fatty acids, and, to a lesser extent, ribonucleic acid and the vitamins E, C, and A have pharmacologic effects when given in amounts in excess of what is needed to prevent nutritional deficiency. These effects are exerted primarily via the immune system, and immunoenhancing diets that embody the recently developed principles of nutritional pharmacology have been shown to reduce infectious complications by approximately 75% in surgical patients and hospital stay by more than 20% in surgical patients and patients in the intensive care unit in three independent, prospective, randomized studies, two of which were double-blinded. These findings suggest that specialized diets can be designed that will be of benefit to patients with cancer, atherosclerosis, intestinal diseases, autoimmune diseases, infections, and trauma. However, the interaction of these nutrients in pharmacologic amounts with standard pharmacologic drugs is largely unknown, as are the effects of long-term administration of specialized diets to treat these conditions.
Immune and metabolic effects of arginine in the surgical patient. Arginine enhances immune function and promotes nitrogen retention in animal models, but its immunomodulatory effects in surgical patients are unknown. This randomized, prospective trial evaluated the immune and metabolic effects of supplemental L-arginine (25 g/day, n = 16) or isonitrogenous L-glycine (43 g/day, n = 14) in 30 cancer patients undergoing major operation.
Two groups of patients received either arginine or glycine for 7 days after surgery as a supplement to a graduated enteral diet. Nitrogen balance was measured daily, and immune parameters were determined both before and after surgery, on Days 1, 4, and 7. The Tlymphocyte response to concanavalin A (con A) and PHA and dual marker phenotype analysis of lymphocyte (CD2, CD4, CD4/DR, CD8, CD8/DR) and macrophage (M3/DR) subsets were determined. Mean age, degree of preoperative weight loss, disease stage, number of perioperative transfusions, and calorie and nitrogen intake were similar for the groups studied.
Mean daily nitrogen balance (-2.3 g/day in the arginine group vs. -3.9 g/day in the glycine group)
was not significantly different between the two groups, but positive mean nitrogen balance was Can daily dietary arginine supplement affect the function and subpopulation of lymphocytes in patients with advanced gastric cancer? Digestion. 1993; 54(2) :118-24.
Wu CW, Chi CW, Chiu CC, Wu HS, Liu WY, P'eng FK, Wang SR.
Department of Surgery, Veterans General Hospital-Taipei, Taiwan, ROC.
Since arginine can stimulate lymphocyte proliferation in the healthy human, its effect on lymphocyte proliferation in vitro was studied in 7 patients with far advanced gastric cancer.
These patients with normal nourishment were ambulatory and could consume a regular diet. A daily dietary supplement of 30 g arginine for 7 days did not alter the total lymphocyte counts or the T/B cell ratio in the peripheral blood. Enhancement of lymphocyte proliferation in response to mitogen stimulation was not observed. Furthermore, an in vitro study on the effect of arginine on phytohemagglutinin-stimulated lymphocyte proliferation showed that lymphocytes from gastric cancer patients had poorer responses than those obtained from normal subjects, despite the supplement in the culture medium with normal serum, patient serum, or fetal bovine serum.
Arginine ingestion did not impair liver function and had no detectable side effects except McCarter MD, Gentilini OD, Gomez ME, Daly JM.
Department of Surgery, New York Hospital-Cornell University Medical College, NY 100021, USA.
BACKGROUND: Early postoperative enteral nutrition with immune-enhancing supplements has helped to restore immune function and reduce infectious complications in patients with cancer undergoing major gastrointestinal operations. The aim of this study was to evaluate the effectiveness of similar supplements (containing arginine and arginine plus omega-3 fatty acids) given preoperatively for 1 week before cancer surgery. METHODS: In this randomized, double-blinded study, patients scheduled to undergo elective resection of upper gastrointestinal tumors were given one of three different oral liquid supplemental diets (control, arginine, arginine plus omega-3 fatty acids)
to be taken each day for 7 days before surgery. Blood samples were obtained upon enrollment, on the morning of surgery, and on postoperative day 1 for analysis of immunologic function. RESULTS: Mean serum ornithine (a metabolite of arginine) levels were significantly higher compared with controls, but no significant increase in mean serum arginine levels was noted on the morning of surgery for those patients who received arginine as part of the supplement. In conjunction with these findings, there were no differences among groups in mean lymphocyte mitogenesis, mean peripheral blood mononuclear cell production of cytokines, or clinical outcomes.
CONCLUSIONS: Use of oral liquid supplements in this fashion did not improve lymphocyte proliferation or monocyte functions in patients with cancer undergoing major surgery.
Recovery of low thymic hormone levels in cancer patients by lysine-arginine combination. Int J Immunopharmacol. 1990; 12(4) :365-71. patients receiving an isocaloric, isonitrogenous formula with fiber enteral formula (group II). RESULTS: No significant intergroup differences in the trend of the three plasma proteins (albumin, transferrin, prealbumin) Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr. 2001 and survival in severely malnourished (weight loss >10% of body weight) head and neck cancer patients undergoing major surgery. DESIGN: Forty-nine patients were randomly assigned to receive 1) no preoperative and standard postoperative tube feeding, 2) standard preoperative and postoperative tube feeding, or 3) arginine-supplemented preoperative and postoperative tube feeding. RESULTS: Patients in both prefed groups received approximately 9 d of preoperative tube feeding, resulting in energy intakes of 110% and 113% of calculated needs (compared with 79% in the control group; P = 0.007). Compared with no preoperative feeding, preoperative enteral nutrition did not significantly improve nutritional status or any of the studied biochemical or immunologic indexes. Major postoperative complications occurred in 53%, 47%, and 59% of patients in study groups 1, 2, and 3 (NS). A trend was seen toward better survival in the argininesupplemented group (P = 0.15). Secondary analysis showed that survivors had better human leukocyte antigen-DR expression on monocytes (P = 0.05) and higher endotoxin-induced cytokine production (P = 0.010 for tumor necrosis factor alpha and P = 0.042 for interleukin 6) at the start of the study than did patients who died. CONCLUSIONS: Nine days of preoperative Protein metabolism in the cancer patient. Biochimie. 1994; 76(8) :713-7.
Garlick PJ, McNurlan MA.
Department of Surgery, State University of New York, Health Sciences Center, Stony Brook 11794-8191, USA.
The 'flooding' method has been widely used for measuring protein synthesis in animal tissues in vivo and in vitro, employing radioactively labelled amino acids, because it minimises errors in determining the specific radioactivity of the direct precursor of protein synthesis. This approach has now been modified for measuring protein synthesis rates in tumours and healthy tissues of humans by injection of the stable isotopic labels, [1(-13)C]leucine or [2H5]phenylalanine, followed by tissue sampling during surgery. Based on the observation that rates of protein synthesis correlate with changes in the expression of cell proliferation markers, we have suggested that changes in protein synthesis in tumours can be used as indices of changes in tumour growth. Measurements in colorectal cancer patients have shown that protein synthesis is stimulated 80% by feeding, suggesting that the tumour is not a pure parasite, but responds to exogenous nutrients. Moreover, when the composition of the amino acids given to the patient was changed from a balanced mixture to one supplemented with branched chain amino acids, the response of the tumour to feeding was significantly diminished, suggesting that tumour growth might be modulated by diet composition. Dietary supplements of arginine have been shown previously to inhibit tumour growth in animals, probably by activating the immune system. However, in breast cancer patients arginine stimulated tumour protein synthesis, suggesting that arginine might have separate stimulatory effects on the tumour and the immune system, the outcome depending on which effect predominates.
The nitric oxide pathway: is L-arginine a gate to the new millennium medicine?
A meta-analysis of L-arginine effects. 
